Brokerages Set Paratek Pharmaceuticals, Inc. (PRTK) PT at $42.71

Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) has received a consensus rating of “Buy” from the ten research firms that are currently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation, six have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price objective among analysts that have covered the stock in the last year is $42.71.

Several equities research analysts have commented on PRTK shares. BidaskClub cut Paratek Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, August 4th. Zacks Investment Research upgraded Paratek Pharmaceuticals from a “hold” rating to a “buy” rating and set a $21.00 target price on the stock in a research note on Saturday, August 5th. Cantor Fitzgerald restated an “overweight” rating on shares of Paratek Pharmaceuticals in a research note on Tuesday, August 8th. Raymond James Financial, Inc. restated a “strong-buy” rating and issued a $36.00 target price on shares of Paratek Pharmaceuticals in a research note on Thursday, August 24th. Finally, ValuEngine cut Paratek Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Monday, September 18th.

Several large investors have recently bought and sold shares of PRTK. Bank of New York Mellon Corp increased its position in shares of Paratek Pharmaceuticals by 17.5% during the 1st quarter. Bank of New York Mellon Corp now owns 84,045 shares of the specialty pharmaceutical company’s stock worth $1,618,000 after purchasing an additional 12,505 shares during the last quarter. American International Group Inc. increased its position in shares of Paratek Pharmaceuticals by 34.1% during the 1st quarter. American International Group Inc. now owns 11,111 shares of the specialty pharmaceutical company’s stock worth $214,000 after purchasing an additional 2,824 shares during the last quarter. TIAA CREF Investment Management LLC increased its position in shares of Paratek Pharmaceuticals by 11.7% during the 1st quarter. TIAA CREF Investment Management LLC now owns 75,076 shares of the specialty pharmaceutical company’s stock worth $1,445,000 after purchasing an additional 7,844 shares during the last quarter. Vanguard Group Inc. increased its holdings in shares of Paratek Pharmaceuticals by 9.5% during the 1st quarter. Vanguard Group Inc. now owns 724,300 shares of the specialty pharmaceutical company’s stock worth $13,942,000 after acquiring an additional 63,121 shares during the last quarter. Finally, Geode Capital Management LLC increased its holdings in shares of Paratek Pharmaceuticals by 10.7% during the 1st quarter. Geode Capital Management LLC now owns 148,962 shares of the specialty pharmaceutical company’s stock worth $2,867,000 after acquiring an additional 14,392 shares during the last quarter. 81.17% of the stock is currently owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY NOTICE: “Brokerages Set Paratek Pharmaceuticals, Inc. (PRTK) PT at $42.71” was first reported by Community Financial News and is owned by of Community Financial News. If you are accessing this piece of content on another publication, it was illegally copied and reposted in violation of US & international copyright and trademark laws. The legal version of this piece of content can be viewed at https://www.com-unik.info/2017/11/22/brokerages-set-paratek-pharmaceuticals-inc-prtk-pt-at-42-71.html.

Paratek Pharmaceuticals (PRTK) traded up $0.55 during midday trading on Friday, reaching $20.65. The company’s stock had a trading volume of 237,609 shares, compared to its average volume of 585,505. The company has a current ratio of 10.53, a quick ratio of 10.53 and a debt-to-equity ratio of 0.49. Paratek Pharmaceuticals has a 12-month low of $12.75 and a 12-month high of $29.00.

About Paratek Pharmaceuticals

Paratek Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics based upon tetracycline chemistry. Its product candidates are the antibacterials omadacycline and sarecycline. Omadacycline is an antibiotic being developed for use as an empiric monotherapy option for patients suffering from serious, community-acquired bacterial infections.

Analyst Recommendations for Paratek Pharmaceuticals (NASDAQ:PRTK)

What are top analysts saying about Paratek Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Paratek Pharmaceuticals Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit